Rational use of immunodiagnostic tools for tuberculosis infection: Guidelines and cost effectiveness studies

New Microbiologica

Volumn 33, Issue 2, 2010, Pages 93-107

  Amicosante, Massimo ^a,b   Ciccozzi, Massimo ^d   Markova, Roumiana ^c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b ProxAgen Ltd   (Bulgaria)

^c NATIONAL CENTER OF INFECTIOUS AND PARASITIC DISEASES   (Bulgaria)

^d ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Guidelines; IGRA; Immunodiagnosis; Latent infection; Tuberculosis

Indexed keywords

BACTERIAL ANTIGEN; GAMMA INTERFERON; MYCOBACTERIUM TUBERCULOSIS ANTIGENS;

COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; IMMUNOLOGICAL PROCEDURES; IMMUNOLOGY; LUNG TUBERCULOSIS; METHODOLOGY; MYCOBACTERIUM TUBERCULOSIS; PRACTICE GUIDELINE; REVIEW; STANDARD; TUBERCULOSIS;

ANTIGENS, BACTERIAL; COST-BENEFIT ANALYSIS; GUIDELINES AS TOPIC; HUMANS; IMMUNOLOGIC TESTS; INTERFERON-GAMMA; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; TUBERCULOSIS, PULMONARY;

MYCOBACTERIUM;

EID: 77952699949     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. th Edition.
2. ANDERSON P., MUNK ME., POLLOCK JM., DOHERTY TM. (2000). Specific immune-based diagnosis of TB. Lancet. 356, 1099-1104.
3. ANDERSEN P., MUNK ME., POLLOCK JM., DOHERTY TM. (2000). Specific immune-based diagnosis of tuberculosis. Lancet. 356, 1099-1104.
4. AREND S.M., ANDERSEN P., VAN MEUGAARDEN K.E., SKJOT R.L., SUBRONTO Y.W., VAN DISSEL J.T., OTTENHOFF T.H. (2000). Detection of active tuberculosis infection by T cell responses to early-secreted antigenic target 6-kDa protein and culture filtrate protein 10. J. Infect. Dis. 181, 1850-1854.
5. AUSTRALIAN GOVERNMENT., DEPARTMENT OF HEALTH AND AGEING. National Tuberculosis Advisory Committee, Position statement on Interfero-gamma release immunoassays in the detection of latent tuberculosis infection, October 2007.
6. AUSTRALIAN SOCIETY FOR INFECTIOUS DISEASES REFUGEE HEALTH GUIDELINES WORKING GROUP. Diagnosis, management and prevention of infections in recently arrived refugees, 2009.
7. BEHR M.A., WILSON M.A., GILL W.P., ET AL. (1999). Comparative genomics of BCG vaccines by whole genome DNA microarray. Science. 284, 1520-1523.
8. BEGLINGER C., DUDLER J., MOTTET C., NICOD L., SEIBOLD E, VILLIGER P., ZELLWEGER J. (2007). Screening fortuberculosis infection before the initiation of an anti-TNF-alpha therapy. Swiss Med. Wkly. 620-622.
9. BROCK L., MUNK ME., KOK-JENSEN A., ANDERSEN P. (2001). Performance of whole blood IFN-gamma test for tuberculosis diagnosis based on PPD or the specific antigens ESAT-6 and CFP-10. Int. J. Tuberc. Lung. Dis. 5, 462-467.
10. CANADIAN TUBERCULOSIS COMMITTEE. (2008). Updated Recommendations on Interferon Gamma Release Assays for Latent Tuberculosis Infection. An Advisory Committee Statement (ACS). Can. Commun. Dis. Rep. 34 (ACS-6), 1-13.
11. CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC). Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide., 2000-2004. (2006). MMWR Morb. Mortal. Wkly. Rep. 55, 301-305.
12. CDC. Guidelines for Using the QuantiFERON®Test for Diagnosing Latent Mycobacterium tuberculosis Infection. MMWR., January 31, 2003/52 (RR02). 15-18.
13. CDC/NIH/IDSA Guidelines 2009. Guidelines for prevention and treatment of Opportunistic infections in HIV-infected adults and adolescents. MMWR (2009) 58.
14. CENTERS FOR DISEASE CONTROL. MMWR Dec 16 (2005). Vol.54, No.RR-15.
15. COMMITTEE OF PREVENTION, JAPANESE SOCIETY OF TUBERCULOSIS. (2006). Kekkaku. 81, 393-397.
16. COMMISSE VOOR PRAKTISCHE TUBERCULOSEBESTRIJDING (CPT). Plaatsbepaling van de Interferon Gamma Release Assays bij de diagnostiek van tuberculose. [Dutch Committee for Practical Tuberculosis Control. Positioning of Interferon Gamma Release Assays in the diagnosis of tuberculosis]. October 2007
17. DIEL R., FOREßBOHM M., LOYTVED G., HAAS W., HAUER B., MAFFEI D., MAGDORF K., NIENHAUS A., RIEDER HL., SCHABERG T., ZELLWEGER JR, LODDENKEMPER R. (2007). German Central Committee Against Tuberculosis (Deutsches Zentralkomitee zur Bekämpfung der Tuberkulose - DZK). [Recommendations for contact tracing in tuberculosis (Empfehlungen für die Umgebungsuntersuchungen bei Tuberkulose]. Pneumologie. 61. 440.
18. DIEL R., HAUER B., LODDENKEMPER R., MANGER B., KRÜGER K. (2009). New TB testing recommendations for autoimmune diseases., Germany.Recommendations for tuberculosis screening before initiation of TNF-α-inhibitor treatment in rheumatic diseases. Zeitschrift für Rheumatologie., Volume68, Number 5, July.
19. DIEL R., NIENHAUS A., LODDENKEMPER R. (2007). Costeffectiveness of interferon gamma release assay screening for latent tuberculosis infection treatment in Germany. Chest. 5, 1424-1434. (Pubitemid 46762348)
20. DIEL R., NIENHAUS A., LANGE C., SCHABERG T. (2006). Cost optimization of screening for latent tubercu-losis in close contacts. Eur. Respir. J. 28, 35-44. (Pubitemid 44914258)
21. DE PERIO MA., TSEVAT J., ROSELLE GA., KRALOVIC SM., ECKMAN MH. (2007). The cost-effectiveness of Interferon-Y release assays vs. Tuberculin skin tests for detecting latent tuberculosis infection in healthcare workers. Presented at Infectious Diseases Society of America. Oct.
22. DE PERIO M.A., TSEVAT J., ROSELLE G.A., KRALOVIC S.M., ECKMAN M.H. (2009). Cost-effectiveness of interferon gamma release assays vs tuberculin skin tests in health care workers. Arch. Intern. Med. 169, 179-187.
23. ELABORATO DEI GRUPPI DI STUDIO INFEZIONI E TUBERCOLOSI DELL'ASSOCIAZIONE ITALIANA PNEUMOLOGI OSPEDALIERI (AIPO) E DELLA SOCIETA ITALIANA DI MEDICINA RESPIRATORIA (SIMER). (2006). Documento sull'utilizzo dei nuovi test immunologici per la diagnosi di infezione tubercolare latente.
24. GIRARDI E. (2009). Italian National Guidelines for TB Control. [Draft].
25. Global tuberculosis control, surveillance, planning, financing. WHO report 2007. Geneva., World Health Organization (WHO/HTM/TB/2007.376).
26. GOMEZ J.E., MCKINNEY J.D. (2004). M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinb). 84, 29-44.
27. HARADA N., HIGUCHI K., YOSHIYAMA T., KAWABE Y., FUJITA A., SASAKI Y., HORIBA M., MITARAI S., YONEMARU M., OGATA H., ARIGA H., KURASHIMA A., WADA A., TAKAMORI M., YAMAGISHI F., SUZUKI K., MORI T., ISHKAWA N. (2008). Comparison of the sensitivity and specificity of two whole blood interferon-gamma assays for M. tuberculosis infection. J. Infect. 56, 348-353.
28. HAUTE AUTHORITÉ DE SANTÉ. (2006). Test de détection de la production d'Inteferféron g pour le diagnostic des infections tuberculeuses.
29. HEALTH PROTECTION AGENCY. (2007). Position Statement on the use of Interferon Gamma Assay (IGRA) test for Tuberculosis (TB). October. Available online at www.hpa.org.uk
30. ULRICHS T., MUNK M.E., MOLLENKOPF H., BEHR-PERST S., COLANGELI R., GENNARO M.L., KAUFMANN S.H. (1998). Differential T cell responses to Mycobacterium tuberculosis ESAT6 in tuberculosis patients and healthy donors. Eur. J. Immunol. 28, 3949-3958.
31. HUEBNER R.E., SCHEIN M.F., BASS J.B. JR. (1993). The tuberculin skin test. Clin. Infect. Dis. 17, 968-975.
32. IADEMARCO M.F., CASTRO K.G. (2003). Epidemiology of tuberculosis. Seminars in respiratory infections 18, 225-240.
33. JENSEN P.A., LAMBERT L.A., IADEMARCO M.F., RIDZON R., DHEDA K. (2005). Guidelines for preventing the transmission of Mycobacterium tuberculosis in health care settings 2005. MMWR Recomm. Rep. 54, 1-141.
34. nd Global Symposium on IGRAs., Dubrovnik May 30-June 1.
35. KNCV/EuroTB Use of Gamma-interferon assays in low- and medium-prevalence countries in Europe, a consensus statement of a Wolfheze Workshop organised by KNCV/EuroTB., Vilnius. Sept 2006.
36. LALVANI A., PATHAN A.A., MCSHANE H., ET AL. (2001). Rapid detection of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells. Am. J. Respir. Crit. Care Med. 163, 824-828. (Pubitemid 32275850)
37. LAMBERT L., RAJBHANDARY S., QUAILS N., BUDNICK L., CATANZARO A., COOK S., DANIELS-CUEVAS L., GARBER E., REVES R. (2003). Costs of implementing and maintaining a tuberculin skin test program in hospitals and health departments. Infect. Control Hosp. Epidemiol. 24, 814-820.
38. LAMBERT L., ET AL. (2003). Costs of Implementing and Maintaing a Tuberculin Skin Test Program in Hospitals and Health Departments. Inf. Con. and Hosp. Epidm. 814-821
39. LEE J., ET AL. (2006). Comparison of two commercial interferon-gamma assays for diagnosing Mycobacterium tuberculosis infection. Eur. Respir. J. 28, 24-30. (Pubitemid 44914256)
40. LEYTEN E.M., ET AL. (2007). Effect of tuberculin skin testing on a Mycobacterium tuberculosis-specific IFN-Y assay. Eur. Respir. J. 29, 1212-1216. (Pubitemid 46895383)
41. MAHAIRAS G.G., SABO P.J., HICKEY M.J., SINGH D.C., STOVER C.K. (1996). Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J. Bacteriol. 178, 1274-1282.
42. nd Global Symposium on IGRAs., Dubrovnik May 30-June 1.
43. MAZUREK G.H., JEREB J., LOBUE P., IADEMARCO M.F., METCHOCK B., VERNON A. (2005). Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection. United States. MMWR Recomm. Rep. 54, 49-55.
44. MORI T., SAKATANI M., YAMAGISHI E., TAKASHIMA T., KAWABE Y., NAGAO K., SHIGETO E., HARADA N., MITARAI S., OKADA M., SUZUKI K., INOUE Y., TSUYUGUCHI K., SASAKI Y., MAZUREK G.H., TSUYUGUCHI I. (2004). Specific detection of tuberculosis infection, an interferon-gamma-based assay using new antigens. Am. J. Respir. Crit. Care Med. 170, 59-64.
45. MORI T., HARADA N. (2005). Cost-effectiveness analysis of QuantiFERON-TB 2nd generation used for detection of tuberculosis infection in contact investigations. Kekkaku. 80, 675-686.
46. NATIONAL IMMUNISATION ADVISORY COMMITTEE OF THE ROYAL COLLEGE OF PHYSICIANS OF IRELAND. Immunisation Guidelines for Ireland., 2008 Edition.
47. NIENHAUS A., SCHABLON A., LE B CLE C., SIANO B., DIEL R. (2008). Evaluation of the interferon-release assayin healthcare workers. Int. Arch. Occup. Environ. Health. 81, 295-300.
48. OXLADE O., SCHWARTZMAN K., MENZIES D. (2007). Interferon-gamma release assays and TB screening in high-income countries, a cost/effectiveness analysis. Int. J. Tuberc. Lung. Dis. 11, 16-26.
49. nd Global Symposium on IGRA. Dubrovnik, May 30 - June 1.
50. PANEL ON ANTIRETROVIRAL GUIDELINES FOR ADULT AND ADOLESCENTS. (2008). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. US Department of Health and Human Services. Jan 29. 1-128.
51. RAVN P., DEMISSIE A., EGUALE T., WONDWOSSON H., LEIN D., AMOUDY H.A., MUSTAFA A.S., JENSEN A.K., HOLM A., ROSENKRANDS I., OFTUNG E., OLOBO J., VON REYN E, ANDERSEN P. (1999). Human T cell responses to the ESAT-6 antigen from Mycobacterium tuberculosis. J. Infect. Dis. 179, 637-645.
52. RECOMMENDATIONS OF THE SPANISH SOCIETY OF PULMONOLOGY AND THORACIC SURGERY (SEPAR). (2008). Diagnosis and Treatment of Tuberculosis. Arch Bronconeumol. 44, 551-566.
53. SOLOVIC I. (2008). National Institute for TB., Lung Diseases and Thoracic Surgery, Slovakia.
54. SORENSEN A.L., NAGAI S., HOUEN G., ANDERSEN P., ANDERSEN A.B. (1995). Purification and characterization of a low-molecular-mass T-cell antigen secreted by Mycobacterium tuberculosis. Infect. Immun. 631, 710-717.
55. SWISS LUNG LEAGUE. (2005). Erkennung der Tuberkuloseinfektion mittels Bluttest (Interferon-gamma). Detection of latent tuberculosis using a blood test (Interferon-Gamma). Berne, Swiss Federal Office of Public Health (actualised 19 December 2005).
56. THWAITES G., FISHER M., HEMINGWAY C., SCOTT G., SOLOMON T., INNES J. (2009). British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J. Infect. 59, 167-187
57. TUFARIELLO J.M., CHAN J., FLYNN J.L. (2003). Latent tuberculosis, mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect. Dis. 3, 578-590.
58. UK NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE (NICE). (2006). National clinical guideline for diagnosis, management, prevention and control of tuberculosis and measures for its prevention and control. London, Royal College of Physicians.
59. UK NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE (NICE). Tuberculosis clinical guideline - full guideline, second consultation. http//www. nice.org.uk/guidance/index.
60. WORLD HEALTH ORGANIZATION (WHO). (2006). Tuberculosis Fact sheet No 104 - Global and regional incidence. March 2006. Retrieved on 6 October.
61. VAN PINXTEREN L.A., RAVN P., AGGER E.M., POLLOCK J., ANDERSEN P. (2000). Diagnosis of tuberculosis based on the two specific antigens ESAT-6 and CFP10. Clin. Diagn. Lab. Immunol. 7, 155-160.